Zenas BioPharma Reports Third Quarter 2024 Financial Results and ...

4 days ago · WALTHAM, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical …

$33
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results And ...

1 week from now

4 days ago · Third quarter 2024 financial results for the quarter ended September 30, 2024. Research and development (R&D) expenses were $33.5 million for the quarter ended …

nasdaq.com

$258
OFF

Zenas Biopharma, Inc. (ZBIO) 8-K Earnings Release - Nov 2024

1 week from now

4 days ago · Exhibit 99.1 . Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates -Completed initial public offering, raising $258.7 million in gross …

last10k.com

$5.02
OFF

Zenas BioPharma Reports Q3 EPS ($5.02), Consensus ($9.33)

1 week from now

4 days ago · Zenas BioPharma reports Q3 EPS ($5.02), consensus ($9.33) November 12, 2024 — 07:33 am EST. Written by TheFly for TipRanks ->. “In the third quarter, we successfully …

nasdaq.com

$258
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results And ...

1 week from now

4 days ago · -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company …

marketscreener.com

$1
OFF

Cue Biopharma Reports Third Quarter 2024 Financial Results And …

1 week from now

1 day ago · Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for the three …

businessinsider.com

$1
OFF

Cue Biopharma Reports Third Quarter 2024 Financial Results And …

1 week from now

1 day ago · Third Quarter 2024 Financial Results Collaboration revenue increased by $1.2 million to $3.3 million for the three months ended September 30, 2024, from $2.1 million for the three …

nasdaq.com

$753
OFF

Apogee Therapeutics Provides Pipeline Progress And Reports Third ...

1 week from now

4 days ago · Third Quarter 2024 Financial Results. Cash Position: As of September 30, 2024, Apogee had cash, cash equivalents and marketable securities of $753.8 million. Apogee …

stockhouse.com

$258
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results And ...

1 week from now

4 days ago · -Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab, and support company …

quantisnow.com

$184
OFF

I-Mab Reports Third Quarter 2024 Results - Nasdaq

1 week from now

Sep 30, 2024 · Third Quarter 2024 Financial Results Cash Position As of September 30, 2024 , the Company had cash and cash equivalents, and short-term investments of $184.4 million , …

nasdaq.com

12%
OFF

Mereo BioPharma Reports Third Quarter 2024 Financial Results …

1 week from now

4 days ago · Third Quarter 2024 Financial Results Total research and development (R&D) expenses decreased by $0.4 million, or 12%, from $3.6 million in the third quarter of 2023 to …

businessinsider.com

35%
OFF

Theravance Biopharma, Inc. Reports Third Quarter 2024 Financial …

1 week from now

3 days ago · While Viatris records the total net sales of YUPELRI within its financial statements, Theravance Biopharma's implied 35% share of net sales of YUPELRI for the third quarter of …

prnewswire.com

$258
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results And ...

1 week from now

-Completed initial public offering, raising $258.7 million in gross proceeds, to fund the expanded clinical development of lead product candidate, obexelimab,

centralcharts.com

$258
OFF

Zenas BioPharma Reports Third Quarter 2024 Financial Results And ...

1 week from now

ZBIO Zenas BioPharma Inc Zenas BioPharma Reports Third Quarter 2024 Financial Results and Provides Corporate Updates-Completed initial public offering, raising $258.7 million in gross …

advfn.com

FAQs about Zenas BioPharma Reports Third Quarter 2024 Financial Results and ... Coupon?

Does Zenas Biopharma have an IPO?

WALTHAM, Mass., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas”), (Nasdaq: ZBIO) a clinical-stage global biopharmaceutical company committed to being a leader in the development and ... Two small IPOs and two SPACs debuted this past week - Pheton Holdings, Powell Max, Vine Hill Capital, and Andretti Acquisition II, respectively. ...

Will Zenas Biopharma raise $100 million?

Zenas BioPharma, a Phase 3 biotech developing therapies for autoimmune and inflammatory diseases, filed on Thursday with the SEC to raise up to $100 million in an initial public offering. However, thi... ...

Will Zenas Biopharma go public?

However, thi... Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings. Zenas BioPharma has filed to go public with an IPO on the NASDAQ. ...

What did Zenas do in the third quarter?

“In the third quarter, we successfully completed our initial public offering, providing capital to fund our growth strategy for the Company and expand the clinical development of our lead product candidate, obexelimab, for the treatment of autoimmune diseases,” said Lonnie Moulder, Founder and Chief Executive Officer of Zenas. ...

How many ordinary shares did Mereo BioPharma issue in 2024?

Total ordinary shares issued as of September 30, 2024, were 773,672,299. Total ADS equivalents as of September 30, 2024, were 154,734,459, with each ADS representing five ordinary shares of the Company. About Mereo BioPharma Mereo BioPharma is a biopharmaceutical company focused on the development of innovative therapeutics for rare diseases. ...

What happened to Mereo BioPharma Group plc?

LONDON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc (NASDAQ: MREO) (“Mereo” or the “Company”), a clinical-stage biopharmaceutical company focused on rare diseases, today announced its financial results for the third quarter ended September 30, 2024, and provided an update on recent corporate highlights. ...